[1]卢谦益.阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效[J].眼科新进展,2019,39(4):340-342.[doi:10.13389/j.cnki.rao.2019.0076]
　LU Qian-Yi.Intravitreal aflibercept injection for the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(4):340-342.[doi:10.13389/j.cnki.rao.2019.0076]
点击复制

阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年4期
页码:
340-342
栏目:
应用研究
出版日期:
2019-04-05

文章信息/Info

Title:
Intravitreal aflibercept injection for the treatment of diabetic macular edema
作者:
卢谦益
215006　江苏省苏州市，苏州大学附属第一医院眼科
Author(s):
LU Qian-Yi
Department of Ophthalmology，the First Affiliated Hospital of Soochow University，Suzhou 215006，Jiangsu Province，China
关键词:
阿柏西普; 糖尿病黄斑水肿; 血管内皮生长因子
Keywords:
aflibercept; diabetic macular edema; vascular endothelial growth factor
分类号:
R774
DOI:
10.13389/j.cnki.rao.2019.0076
文献标志码:
A
摘要:
目的　探讨阿柏西普经玻璃体内注射治疗糖尿病黄斑水肿的临床疗效。方法　选取2018年6月至7月来我院眼科就诊的糖尿病黄斑水肿患者15例15眼，通过玻璃体内注射阿柏西普进行治疗。注射前和注射后1个月、2个月门诊复查时，分别检查患者最佳矫正视力（best corrected vision acuity，BCVA）和眼压，并行黄斑区光学相干断层成像，记录黄斑中心凹视网膜厚度（central foveal thickness，CFT）等。结果　患者术前BCVA为0.31±0.12；阿柏西普玻璃体内注射术后1个月BCVA为0.44±0.12，和术前相比差异有统计学意义（P=0.009）；术后2个月BCVA为0.53±0.13，和术前相比差异亦有统计学意义（P<0.001）。但术后两组数据之间差异无统计学意义（P=0.132）。黄斑区光学相干断层成像检查显示，术前CFT为（354.30±89.52）μm；阿柏西普玻璃体内注射术后1个月CFT为（233.10±49.54）μm，显著低于术前，差异有统计学意义（P<0.001）；术后2个月CFT为（198.60±41.88）μm，显著低于术前，差异亦有统计学意义（P<0.001）。术后2个月CFT显著低于术后1个月，差异有统计学意义（P=0.038）。术后1个月、2个月间患者眼压以及与术前相比，差异均无统计学意义（均为P>0.05）。结论　经玻璃体内注射阿柏西普可有效减轻糖尿病黄斑水肿病变程度，提高视力。
Abstract:
Objective　To observe the clinical effect of intravitreal injection of aflibercept for patients with diabetic macular edema （DME）.Methods　Totally，fifteen eyes of fifteen patients with DME who visited the Department of Ophthalmology，the First Affiliated Hospital of Soochow University，between June and July 2018 were included.Intravitreal aflibercept injection was conducted for treatment.The best corrected vision acuity （BCVA） and optical coherence tomography （OCT） were examined，and the central foveal thickness （CFT） and intraocular pressure were recorded before the injection，and 1 month，2 months after the injection at the follow-up time.Results　The BCVA in 1 month after injection was 0.44±0.12，which was significantly higher compared to that before injection （0.31±0.12） （P=0.009）.Also，the BCVA in 2 months after injection was 0.53±0.13，which was significantly higher compared to that before injection （P<0.001）.There was no significant difference in BCVA between 1 month and 2 months after injection （P=0.132）.The CFT examined by OCT in 1 month after injection was （233.10±49.54）μm，which was significantly decreased compared to that before injection［ （354.30±89.52）μm］（P<0.001）.Also，the CFT in 2 months after injection was （198.60±41.88）μm，which was significantly decreased compared to that before injection（P<0.001）.Besides，the CFT in 2 months after injection was significantly decreased compared to that in 1 month after injection （P=0.038）.There was no significant difference of intraocular pressure between 1 month and 2 months after injection and before injection （both P>0.05）.Conclusion　It is found that intravitreal injection of aflibercept can efficiently alleviate macular edema and promote BCVA for patients with DME.

参考文献/References:

［1］　CHEUNG G C，YOON Y H，CHEN L J，CHEN S J，GEORGE T M，LAI T Y，et al.Diabetic macular oedema：evidence-based treatment recommendations for Asian countries［J］.Clin Exp Ophthalmol，2018，46（1）：75-86.
［2］　LU Q，LU L，CHEN W，CHEN H，XU X，ZHENG Z.RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy［J］.Graefes Arch Clin Exp Ophthalmol，2015，253（5）：669-680.
［3］　LU Q，LU P，CHEN W，LU L，ZHENG Z.ANGPTL-4 induces diabetic retinal inflammation by activating Profilin-1［J］.Exp Eye Res，2018，166：140-150.
［4］　YAU J W，ROGERS S L，KAWASAKI R，LAMOUREUX E L，KOWALSKI J W，BEK T，et al.Global prevalence and major risk factors of diabetic retinopathy［J］.Diabetes Care，2012，35（3）：556-564.
［5］　LU Q，ZOU W，CHEN B，ZOU C，ZHAO M，ZHENG Z.ANGPTL-4 correlates with vascular endothelial growth factor in patients with proliferative diabetic retinopathy［J］.Graefes Arch Clin Exp Ophthalmol，2016，254（7）：1281-1288.
［6］　LU Q，LU L，CHEN W，LU P.Expression of angiopoietin-like protein 8 correlates with VEGF in patients with proliferative diabetic retinopathy［J］.Graefes Arch Clin Exp Ophthalmol，2017，255（8）：1515-1523.
［7］　LU Q，ZOU C，CAO H，ZHAO M，YU S，QIU Q，et al.Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma［J］.Acta Ophthalmol，2016，94（4）：414-415.
［8］　PAPADOPOULOUS N，MARTIN J，RUAN Q，RAFIQUE A，ROSCONI M P，SHI E，et al.Binding and neutralization of vascular endothelial growth factor （VEGF） and related ligands by VEGF Trap，ranibizumab and bevacizumab［J］.Angiogenesis，2012，15（2）：171-185.
［9］　RUDGE J S，HOLASH J，HYLTON D，RUSSEII M，JIANG S，LEIDICH R，et al.VEGF Trap complex formation measures production rates of VEGF，providing a biomarker for predicting efficacious angiogenic blockade［J］.Proc Natl Acad Sci USA，2007，104（47）：18363-18370.
［10］　FAUSER S，SCHWABECKER V，MUETHER P S.Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration［J］.Am J Ophthalmol，2014，158（3）：532-536.
［11］　MUETHER P S，HERMANN M M，DROGE K，KIRCHHOF B，FAUSER S.Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration［J］.Am J Ophthalmol，2013，156（5）：989-993.
［12］　LI J，LU Q，LU P.Quantitative proteomics analysis of vitreous body from type 2 diabetic patients with proliferative diabetic retinopathy［J］.BMC Ophthalmol，2018，18（1）：151.

相似文献/References:

[1]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[2]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[3]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[4]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[5]刘斌,杨玉霞,刘杏,等.玻璃体内注射Lucentis治疗糖尿病黄斑水肿[J].眼科新进展,2015,35(1):045.[doi:10.13389/j.cnki.rao.2015.0013]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al.Intravitreal injection of Lucentis for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):045.[doi:10.13389/j.cnki.rao.2015.0013]
[6]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):246.[doi:10.13389/j.cnki.rao.2015.0066]
[7]徐浩,白宁艳,吕鹏,等. 雷珠单抗玻璃体内注射与黄斑部格栅样光凝联合治疗糖尿病性黄斑水肿的疗效观察[J].眼科新进展,2015,35(8):781.[doi:10.13389/j.cnki.rao.2015.0215]
　XU Hao,BAI Ning-Yan,LV Peng,et al. Intravitreous injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):781.[doi:10.13389/j.cnki.rao.2015.0215]
[8]董秀清,冯松福,柯晓云.应用光学相干断层扫描量化评估糖尿病黄斑水肿的临床研究[J].眼科新进展,2017,37(2):133.[doi:10.13389/j.cnki.rao.2017.0035]
　DONG Xiu-Qing,FENG Song-Fu,KE Xiao-Yun.Evaluating diabetic macular edema quantificationally by optical coherence tomography[J].Recent Advances in Ophthalmology,2017,37(4):133.[doi:10.13389/j.cnki.rao.2017.0035]
[9]莫香红,黄敏丽.糖尿病黄斑水肿的激光治疗进展[J].眼科新进展,2017,37(7):688.[doi:10.13389/j.cnki.rao.2017.0175]
　MO Xiang-Hong,HUANG Min-Li.Laser treatment progress for diabetic macular edema[J].Recent Advances in Ophthalmology,2017,37(4):688.[doi:10.13389/j.cnki.rao.2017.0175]
[10]邹洪强,田洪芹,张艳平,等.阿柏西普治疗眼底血管性疾病的临床研究新进展[J].眼科新进展,2017,37(9):894.[doi:10.13389/j.cnki.rao.2017.0227]
　ZOU Hong-Qiang,TIAN Hong-Qin,ZHANG Yan-Ping,et al.Recent advances in clinical research on aflibercept treating fundus vascular diseases[J].Recent Advances in Ophthalmology,2017,37(4):894.[doi:10.13389/j.cnki.rao.2017.0227]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81700847）；江苏省自然科学基金资助（编号：BK20170365）
更新日期/Last Update: 2019-04-15